These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 17327908)
41. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer]. Takigawa N; Ohnoshi T; Ueoka H; Horiguchi T; Kiura K; Tabata M; Segawa Y; Shibayama T; Genba K; Matsumura T Gan To Kagaku Ryoho; 1993 Jul; 20(9):1221-6. PubMed ID: 8392827 [TBL] [Abstract][Full Text] [Related]
42. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Hansen LT; Lundin C; Spang-Thomsen M; Petersen LN; Helleday T Int J Cancer; 2003 Jul; 105(4):472-9. PubMed ID: 12712436 [TBL] [Abstract][Full Text] [Related]
43. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity. Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876 [TBL] [Abstract][Full Text] [Related]
44. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma. Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956 [TBL] [Abstract][Full Text] [Related]
45. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Sadava D; Still DW; Mudry RR; Kane SE Cancer Lett; 2009 May; 277(2):182-9. PubMed ID: 19188016 [TBL] [Abstract][Full Text] [Related]
46. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856 [TBL] [Abstract][Full Text] [Related]
47. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Sartorius UA; Krammer PH Int J Cancer; 2002 Feb; 97(5):584-92. PubMed ID: 11807782 [TBL] [Abstract][Full Text] [Related]
48. [Role and clinical significance of RLIP76 in regulation of multi-drug resistance of small cell lung cancer]. Haixia P; Yifeng B; Honglin H Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):266-71. PubMed ID: 26462890 [TBL] [Abstract][Full Text] [Related]
49. The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells. Sadava D; Kane SE Biochem Biophys Res Commun; 2017 Nov; 493(1):783-787. PubMed ID: 28847728 [TBL] [Abstract][Full Text] [Related]
50. [Role of SALL4 in regulating multi-drug resistance of small cell lung cancer and its clinical significance]. Liu H; Bai Y; Wang W; Guo L Zhonghua Bing Li Xue Za Zhi; 2014 Sep; 43(9):604-8. PubMed ID: 25471501 [TBL] [Abstract][Full Text] [Related]
51. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Cobos E; Jumper C; Lox C Clin Appl Thromb Hemost; 2003 Jul; 9(3):241-6. PubMed ID: 14507113 [TBL] [Abstract][Full Text] [Related]
52. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Damstrup L; Rude Voldborg B; Spang-Thomsen M; Brünner N; Skovgaard Poulsen H Br J Cancer; 1998 Sep; 78(5):631-40. PubMed ID: 9744504 [TBL] [Abstract][Full Text] [Related]
53. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. LeBeau AM; Sevillano N; King ML; Duriseti S; Murphy ST; Craik CS; Murphy LL; VanBrocklin HF Theranostics; 2014; 4(3):267-79. PubMed ID: 24505235 [TBL] [Abstract][Full Text] [Related]
54. Personalized Therapy of Small Cell Lung Cancer. Schneider BJ; Kalemkerian GP Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804 [TBL] [Abstract][Full Text] [Related]
55. Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2. Hillgenberg M; Schlehofer JR; von Knebel Doeberitz M; Klein-Bauernschmitt P Eur J Cancer; 1999 Jan; 35(1):106-10. PubMed ID: 10211097 [TBL] [Abstract][Full Text] [Related]
56. Correlation of in vitro drug sensitivity testing of long-term small cell lung cancer cell lines with response and survival. Tsai CM; Ihde DC; Kadoyama C; Venzon D; Gazdar AF Eur J Cancer; 1990; 26(11-12):1148-52. PubMed ID: 1963547 [TBL] [Abstract][Full Text] [Related]
57. Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer. Pappot H; Pfeiffer P; Grondahlhansen J; Skov B Int J Oncol; 1997 Jan; 10(1):177-82. PubMed ID: 21533361 [TBL] [Abstract][Full Text] [Related]
58. A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. Caffrey PB; Frenkel GD; McAndrew KL; Marks K In Vivo; 2016 11-12; 30(6):745-749. PubMed ID: 27815457 [TBL] [Abstract][Full Text] [Related]
59. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP. Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892 [TBL] [Abstract][Full Text] [Related]
60. KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer. Simó-Riudalbas L; Pérez-Salvia M; Setien F; Villanueva A; Moutinho C; Martínez-Cardús A; Moran S; Berdasco M; Gomez A; Vidal E; Soler M; Heyn H; Vaquero A; de la Torre C; Barceló-Batllori S; Vidal A; Roz L; Pastorino U; Szakszon K; Borck G; Moura CS; Carneiro F; Zondervan I; Savola S; Iwakawa R; Kohno T; Yokota J; Esteller M Cancer Res; 2015 Sep; 75(18):3936-45. PubMed ID: 26208904 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]